ATS 2018 International Conference - Mobile

Fevipiprant, a Potent Selective Prostaglandin D2 Receptor 2 (DP2) Antagonist, Dose-Dependently Inhibits Pulmonary Inflammation in a Mouse Model of Asthma [Board No. P948]

Location: Board no. P948

Session Type: Thematic Poster Session

Sunday

May

20

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Rachael Profit

PhD
Novartis Institutes for Biomedical Research

Yoshiki Shiraishi

PhD
Tokai University School of Medicine

Lucy Barker

BSc
Novartis Institutes for Biomedical Research

Ian Knowles

PhD, BSc(Hons)
Pneumolabs Ltd

Koichiro Asano

MD
Tokai University;Tokai University Sch. of Med.;Tokai University School of Medicine

Markus Weiss

PhD
Novartis Pharma AG

Tadayoshi Mikami

PhD
Novartis Pharma KK

Daniel Wyss

BSc
Novartis Institutes for Biomedical Research

Gareth Williams

PhD
Novartis Institutes for Biomedical Research

Hollie Smith

BSc
Pneumolabs Ltd

David Sandham

PhD
Novartis Institutes for Biomedical Research

Olivia Robb

BSc
Pneumolabs Ltd

Veit Johannes. Erpenbeck

MD, PhD
Novartis;Novartis Pharma AG

David Budd

PhD
Novartis Institutes for Biomedical Research

View Abstract

Fevipiprant, a Potent Selective Prostaglandin D2 Receptor 2 (DP2) Antagonist, Dose-Dependently Inhibits Pulmonary Inflammation in a Mouse Model of Asthma

Parent Sessions

A35 - ASTHMA CLINICAL STUDIES II
05-20-2018 9:15 AM - 4:15 PM